Related references
Note: Only part of the references are listed.Impact of Dose Reduction on Efficacy: Implications of Exposure-Response Analysis of Palbociclib
Jenny Zheng et al.
TARGETED ONCOLOGY (2021)
A phase II, multicenter study of encorafenib/binimetinib followed by a rational triple-combination after progression in patients with advanced BRAF V600-mutated melanoma (LOGIC2).
Reinhard Dummer et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Real-World Experience of Palbociclib-Induced Adverse Events and Compliance With Complete Blood Count Monitoring in Women With Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer
Geoffrey Alan Watson et al.
CLINICAL BREAST CANCER (2019)
Binimetinib, Encorafenib, and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma
Shatha AbuHammad et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Dual MAPK/CDK Targeting in Melanoma: New Approaches, New Challenges
Ryan J. Sullivan
CANCER DISCOVERY (2018)
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Livnat Jerby-Arnon et al.
CELL (2018)
ASCO 2018 highlights: metastatic breast cancer
Gabriel Rinnerthaler et al.
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY (2018)
Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial
Max Schreuer et al.
LANCET ONCOLOGY (2017)
A phase Ib/II dose-escalation study evaluating triple combination therapy with a BRAF (encorafenib), MEK (binimetinib), and CDK 4/6 (ribociclib) inhibitor in patients (Pts) with BRAF V600-mutant solid tumors and melanoma.
Paolo Antonio Ascierto et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6
Akihiro Yoshida et al.
CANCER RESEARCH (2016)
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
Paolo A. Ascierto et al.
LANCET ONCOLOGY (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
Douglas B. Johnson et al.
EUROPEAN JOURNAL OF CANCER (2015)
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V. Long et al.
LANCET (2015)
The Genetic Evolution of Melanoma from Precursor Lesions
A. Hunter Shain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers
Vipin Yadav et al.
PHARMACOLOGY & THERAPEUTICS (2015)
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
Helen Rizos et al.
CLINICAL CANCER RESEARCH (2014)
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
Grant A. McArthur et al.
LANCET ONCOLOGY (2014)
Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines
Richard J. Young et al.
PIGMENT CELL & MELANOMA RESEARCH (2014)
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Hubing Shi et al.
CANCER DISCOVERY (2014)
Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
Katherine L. Nathanson et al.
CLINICAL CANCER RESEARCH (2013)
A Landscape of Driver Mutations in Melanoma
Eran Hodis et al.
CELL (2012)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Transcriptional regulation of the cyclin D1 gene at a glance
Eric A. Klein et al.
JOURNAL OF CELL SCIENCE (2008)
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
Keiran S. M. Smalley et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Share Paper
